Welcome to our dedicated page for Nektar Therapeutics news (Ticker: NKTR), a resource for investors and traders seeking the latest updates and insights on Nektar Therapeutics stock.
Nektar Therapeutics (Nasdaq: NKTR) generates a steady flow of news tied to its role as a clinical-stage biotechnology company focused on autoimmune and chronic inflammatory diseases. Company announcements emphasize progress with its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), a regulatory T cell stimulator and IL-2 pathway agonist being evaluated in multiple mid-stage trials.
News coverage frequently highlights clinical data from the REZOLVE-AD Phase 2b study in moderate-to-severe atopic dermatitis and the REZOLVE-AA Phase 2b study in severe-to-very-severe alopecia areata. Press releases describe topline results, detailed efficacy and safety outcomes, and analyses in subgroups such as patients with atopic dermatitis and a history of asthma, including Asthma Control Questionnaire (ACQ-5) findings.
Investors and observers can also find updates on regulatory interactions, such as the U.S. Food and Drug Administration granting Fast Track designations for rezpegaldesleukin in atopic dermatitis and alopecia areata. Additional news items cover Nektar’s participation in scientific and investor conferences, late-breaking oral presentations at major dermatology and allergy meetings, and corporate events like equity offerings and compliance updates related to its Nasdaq Capital Market listing.
This news page aggregates these disclosures so readers can follow developments in Nektar’s immunology pipeline, including rezpegaldesleukin and other programs such as NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255. For those tracking NKTR stock or the evolution of Treg-focused therapies, this feed provides a centralized view of clinical milestones, financial communications and key corporate announcements.
Exelixis, Inc. has initiated the dose-escalation stage of the STELLAR-002 trial, exploring XL092, a next-generation tyrosine kinase inhibitor, in combination with immuno-oncology therapies for advanced cancers. Collaborating with Bristol-Myers Squibb and Nektar Therapeutics, the trial aims to assess safety and efficacy among patients with advanced solid tumors. The study will focus on renal cell carcinoma, urothelial carcinoma, and metastatic castration-resistant prostate cancer, with primary endpoints including objective response rates and progression-free survival.
Nektar Therapeutics (NASDAQ:NKTR) presented promising data for its investigational drug NKTR-255 at the 63rd American Society of Hematology Annual Meeting. Initial results from a Phase 1 study show NKTR-255 was well tolerated among patients with relapsed/refractory hematologic malignancies, with 53% achieving disease stabilization. The drug demonstrated potential to enhance CAR-T cell persistence and trigger immune response. Ongoing studies aim to investigate NKTR-255 in combination with current therapies for non-Hodgkin's lymphoma and multiple myeloma, with further results anticipated in 2022.
Nektar Therapeutics (NASDAQ: NKTR) announced upcoming presentations for its cytokine immuno-oncology programs at major conferences. Data for the IL-2 agonist, bempegaldesleukin (BEMPEG), will be showcased at the 2021 ESMO-IO Congress in Geneva from December 8-11. Additionally, the 63rd ASH Annual Meeting in Atlanta will feature presentations for the IL-15 agonist, NKTR-255, on December 11-14. The company will also host a webcast for analysts and investors on December 6 to discuss the findings.
Nektar Therapeutics (NASDAQ: NKTR) announced the appointment of Diana M. Brainard, M.D., as an independent director to its Board of Directors, enhancing its leadership with her extensive experience in healthcare and academia. President Howard W. Robin expressed confidence that her background in clinical development and regulatory strategy will positively impact Nektar's pipeline of immune-oncology and immunology candidates. Dr. Brainard currently serves as CEO of AlloVir and has a history of successful initiatives in manufacturing and business strategy.
Nektar Therapeutics (NKTR) presented data on its immuno-oncology pipeline at the 2021 SITC Annual Meeting. Key highlights include early clinical results from a Phase 1/2 study showing NKTR-255 combined with cetuximab is well tolerated, with 1 patient achieving a confirmed partial response and 5 with stable disease. Additionally, translational data from bempegaldesleukin (BEMPEG) combined with nivolumab and NKTR-262 were presented, suggesting potential efficacy. Nektar plans further studies as dose escalation continues.
Nektar Therapeutics (NASDAQ:NKTR) is set to host a webcast analyst and investor conference call on November 12, 2021, at 12:00 p.m. EST. The event will feature cancer specialists, including Dr. Mehmet Altan and Dr. Alan Tan, and will coincide with the publication of the NKTR-255 poster (Abstract #957) during the 2021 Society for Immunotherapy of Cancer Annual Meeting in Washington, D.C. The call will include insights into ongoing clinical studies and findings on NKTR-255 and its combination therapies.
Nektar Therapeutics (NKTR) reported Q3 2021 financial results, revealing revenues of $24.9 million, down from $30.0 million in Q3 2020. Year-to-date revenues were $76.9 million, significantly lower than $129.5 million for the same period last year, primarily due to $50 million in milestone recognition in 2020. Total operating expenses rose to $138.5 million, while the net loss for Q3 was $129.7 million or $0.70 per share, compared to $108.6 million or $0.61 per share in Q3 2020. The company emphasized progress in clinical trials and upcoming data releases.
Nektar Therapeutics (NKTR) will announce its financial results for Q3 2021 on November 4, 2021, after U.S. markets close. CEO Howard Robin will lead a conference call to discuss the results at 5:00 p.m. ET. Interested parties can access the press release and the live audio webcast via their website. A replay of the conference call will be available until December 6, 2021. Nektar specializes in developing therapies in oncology, immunology, and virology, supported by a robust R&D pipeline.
Nektar Therapeutics (NASDAQ: NKTR) announced a new oncology collaboration with Merck KGaA and Pfizer to study NKTR-255, an interleukin-15 receptor agonist, in combination with avelumab in a Phase II study for urothelial carcinoma. The JAVELIN Bladder Medley study will evaluate this combination as a maintenance therapy for patients who have not progressed on first-line chemotherapy. Nektar will supply NKTR-255, and the trial aims to start enrolling patients in Q1 2022. Both NKTR-255 and avelumab remain investigational and are not yet approved for use together.
Nektar Therapeutics (NKTR) reported a revenue of $28.3 million for Q2 2021, down from $48.8 million in Q2 2020, largely due to a $25 million milestone from Bristol-Myers Squibb recognized in the prior year. Operating costs increased to $138.5 million from $126.6 million, driven by higher R&D and G&A expenses. The net loss widened to $125.5 million or $0.69 per share, compared to $80 million or $0.45 per share in Q2 2020. The company aims for crucial clinical data releases in 2022.
FAQ
What is the current stock price of Nektar Therapeutics (NKTR)?
What is the market cap of Nektar Therapeutics (NKTR)?
